首页> 美国政府科技报告 >Reg IV: A Candidate Marker of Metastatic Hormone Refractory Prostate Cancer

【24h】

Reg IV: A Candidate Marker of Metastatic Hormone Refractory Prostate Cancer

机译：Reg IV：转移性激素难治性前列腺癌的候选标志物

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

In our previous in situ hybridization studies of prostate tissue arrays RegIV was shown to be strongly expressed by a majority of metastatic hormone refractory tumors (HRPC) and weaker RegIV expression was found in a subset of primary tumors but not expressed by normal tissue. Our goal is to better understand the role of RegIV in prostate cancer progression and to determine its possible use as a diagnostic marker for early and metastatic prostate cancers. We have developed and affinity purified a polyclonal anti- RegIV that has successfully been tested by immunohistochemistry on positive and negative controls. In vitro studies show cells overexpressing RegIV have a growth advantage and we have successfully made two si-RegIV constructs to knock down RegIV RNA and protein expression and in vivo studies are currently in progress.

著录项

作者
Reiter, R. E.;
展开▼
作者单位

展开▼
年度 2007
页码 1-8
总页数 8
原文格式 PDF
正文语种 eng
中图分类工业技术;
关键词
Proteins; Metastasis; Polyclonal antibodies; Prostate cancer; Hormones; In vitro analysis; In vivo analysis; Prostate gland; Hybridization; Normality; Histochemistry; Immunochemistry; Cells(Biology); Markers; Tissues(Biology);

机译：蛋白;转移;多克隆抗体;前列腺癌;激素;体外数据;在体内分析;前列腺;杂交;当量浓度;组织化学;免疫化学;将细胞（生物）;标记;组织（生物学）;

相似文献

外文文献
中文文献
专利

1. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. [J] . Hayashi T, Matsubara A, Ohara S, Oncology reports . 2009,第1期

机译：泌尿生殖器官中Reg IV的免疫组织化学分析：Reg IV在前列腺癌中的频繁表达及其作为血清肿瘤标志物的潜在用途。
2. Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based firstline treatment for patients with metastatic hormone-refractory prostate cancer [J] . Giandomenico Roviello MD The International journal of biological markers . 2013,第3期

机译：修订PSA反应率作为基于多西他赛的一线治疗转移性激素难治性前列腺癌患者中总生存期的替代指标的作用的时间
3. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. [J] . Berruti A, Dogliotti L, Bitossi R, The Journal of Urology . 2000,第4期

机译：骨转移性前列腺癌和激素难治性疾病患者骨骼并发症的发生率：在基线评估的骨吸收和形成标志物的预测作用。
4. Hormone Refractory Prostate Cancer: Lessons Learned from the PTEN Prostate Cancer Model [C] . David J. Mulholland, Jing Jiao, Hong W International Symposium on Hormonal Carcinogenesis . 2008

机译：激素难治性前列腺癌：从Pten前列腺癌模型中学到的经验教训
5. Emergence of metastatic hormone refractory disease in prostate cancer after anti-androgen therapy. [D] . Lee, Edmund Chun Yu. 2004

机译：抗雄激素治疗后前列腺癌中转移激素难治性疾病的出现。
6. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion [O] . Fraser Conrad, Xiaodong Zhu, Xin Zhang, -1

机译：靶向难治性转移性前列腺癌细胞过度表达的靶向细胞表面抗原的人抗体：ICAM-1是一种介导前列腺癌细胞入侵的肿瘤抗原
7. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion [O] . 2009

机译：靶向难治性转移性前列腺癌细胞过度表达的靶向细胞表面抗原的人抗体：ICAM-1是一种介导前列腺癌细胞入侵的肿瘤抗原
8. Reg IV. A Candidate Marker of Hormone Refractory Metastatic Prostate Cancer [R] . Reiter, R. E. 2008

机译：Reg IV。激素难治性转移性前列腺癌的候选标志物

Reg IV: A Candidate Marker of Metastatic Hormone Refractory Prostate Cancer

摘要

著录项

相似文献

相关主题

期刊订阅